GDP stands for many things, including Good Distribution Practice. Good Distribution Practice deals with the guidelines for the proper distribution of medicinal products for human use. GDP is defined as: "The measures that need to be considered in the storage, transportation and distribution of any registered product /notified cosmetic and its related materials such that the nature and quality intended is preserved when it reaches the consumer"   The GDP standards describe the distribution process from the manufacturing facilities to the end user,...MORE >

Clinical researches are changing in a lot of ways. The study environment and techniques are incorporating more and more technology-oriented trends in order to keep up with the rest of the industry. Regulations are changing, trials designs become more adaptive, strategies for clinical development optimization are shifting in attempt to be more responsive to relevant diseases, for example, and new treatment methods are tested in order to improve healthcare at rates faster than before. The most important thing, however, is...MORE >

When we compare clinical trials for rare diseases and clinical trials for non-rare diseases we can see that the participation of people in the first type has been said to be extremely low. A recent survey shows that out of 24,088 clinical trials, 2,759 (11, 5 %) of them were defined as rare disease trials in which under 50 individuals are indicated to demonstrate interest in taking part in one of them. In this regard, recruiters experience major difficulties in...MORE >

It is not a secret that clinical research is an industry providing many people with opportunities to have a regional or international career. It is not only a great place to earn a good to high salary, but you can also travel a lot, work towards people’s good fortune and be able to move around different departments and get different experience. Unlike doctor’s profession it is rare clinical research professionals deal directly with patients, which can be sometimes really stressful...MORE >

It takes time, a lot of recourses and substantial research to develop a new drug that is effective and serves a medical purpose. Nevertheless, it has been indicated that not always the process of researching leads to positive and productive outcomes, which becomes a major setback in the Pharmaceutical industry. In order to avoid such drawbacks that prevent the industry from quicker progress, regulators and researchers try to find more advanced ways that will lead to more adequate results. Realizing...MORE >

We can’t deny the fact that according to modern-day equations and measurements, corporate value is equal to the number of external people (users, investors, sponsors etc.) attracted to the service or products being provided. To present it differently, the more sides are involved, the wider impact the business is said to have. In order businesses to be highly effective and more encompassing, they need to reach as many people and parts of the world as possible. It is called globalization...MORE >

Sponsoring clinical trials is integral but not an easy task to do. With the lack of enough resources, researchers are looking for alternatives which will help them reach to a bigger group of people that can help them financially. Their help is important as absence of resources quite often is the reason for a trial failure. In order to fight this sort of difficulties and challenges that stand between the start and the end of clinical projects, researchers are constantly...MORE >

Usually double-blind randomized controlled trials (DBRCTs) are considered to be the gold standard when it comes to eliminating any patient or doctor bias. However, recent studies have pointed out that if researchers want to receive 100% efficacy without results being affected by other factors, the double-blind randomized controlled studies might not be the best choice. Consequently, experts have suggested a much better approach to assessing and conducting various clinical processes. The approach in question is a new study outline that...MORE >

Learning is part of the dynamics of our everydayness and it has a major impact on our personal or professional life. People sign up for various courses and trainings in order to acquire new skills, enhance or reinforce what they already know and polish what they are not so familiar with. Such educational programs are no exception for the Pharmaceutical and Clinical industry. In this regard, the more experienced and knowledgeable sponsors and researchers are, the smoother all the processes...MORE >

Good Distribution Practices or also known as GDP is the official guideline delivered by the World Health Organization to serve as the standards for transporting and distributing pharmaceutical products in order to maintain their high quality and safety. It is a part of the GxP series of regulations (for example Good Clinical Practice, Good Laboratory Practice, Good Manufacturing Practice etc.) which are there to ensure that people using the final pharmaceutical products will be safe. Who needs to comply with the Good...MORE >